Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Aug 28, 2019
Half Yearly Report and Accounts
Aug 16, 2019
New patent granted for Neuren's NNZ-2591 in Japan
Jul 31, 2019
Appendix 4C - quarterly
Jul 29, 2019
Neuren submits 3 NNZ-2591 Orphan Drug applications to FDA
Jul 16, 2019
Neuren receives final payment from Lanstead Capital
May 28, 2019
Results of Meeting
May 28, 2019
Chairman's Address at 2019 Annual Meeting of Shareholders
May 17, 2019
Validation for NNZ-2591 neurodevelopmental disorder pipeline
May 17, 2019
NNZ-2591 positive effects in Pitt Hopkins syndrome model
May 17, 2019
NNZ-2591 positive effects in Angelman syndrome model
Previous
1
2
3
4
Next
